102 results about "Cardiac sudden death" patented technology

A method involves implantably detecting changes in posture of a patient's body. Baroreflex responses to the posture changes are determined. An autonomic tone of the patient is determined based on the baroreflex responses. Based on the autonomic tone, various patient susceptibilities to disease may be determined, including susceptibilities to heart disease, arrhythmia, and / or sudden cardiac death.

A leadless implantable cardioverter defibrillator (5) for treatment of sudden cardiac death includes a controller and at least one remote module. The defibrillator does not require transvenous / vascular access for intracardiac lead placement. The controller is leadless and uses subcutaneous tissue in proximity of the chest and abdomen for both sensing and defibrillation. The controller and one or more remote sensors sense a need for defibrillation and wireless communicate with the controller. The controller and one of the sensors discharge a synchronized defibrillation pulse to the surrounding subcutaneous tissue in proximity to the heart.

The present invention relates to an implantable cardioverter-defibrillator or pacemaker whose standard circuitry is used to trend a physiological cardiac parameter using intra-cardiac impedance measurements. The trend information may be used to predict the onset of a sudden cardiac death (SCD) event. By being able to predict the onset of an SCD event, patients and their physicians may be forewarned of a life-threatening event allowing them to respond accordingly. The trend information may also be used to predict the efficacy of cardiac-related medications, monitor progress of congestive heart failure, detect the occurrence of myocardial infarction, or simply track changes in sympathetic tone.

A device that calculates a sudden cardiac death score based on acquired patient data. A system and method that combines independent indications of sudden cardiac death to predict sudden cardiac death. The system can include various cardiology test systems interconnected to a sudden cardiac death prediction system.

A system and method for assessing a patient's risk of sudden cardiac death. One method of the invention can include acquiring patient data at one of a plurality of healthcare locations, identifying the patient as being worthy of an on-going sudden cardiac death risk assessment based on the acquired patient data, and performing the on-going sudden cardiac death risk assessment whenever new patient data is acquired at any one of the plurality of healthcare locations.

The present invention relates to an implantable cardioverter-defibrillator or pacemaker whose standard circuitry is used to trend a physiological cardiac parameter using intra-cardiac impedance measurements. The trend information may be used to predict the onset of a sudden cardiac death (SCD) event. By being able to predict the onset of an SCD event, patients and their physicians may be forewarned of a life-threatening event allowing them to respond accordingly. The trend information may also be used to predict the efficacy of cardiac-related medications, monitor progress of congestive heart failure, detect the occurrence of myocardial infarction, or simply track changes in sympathetic tone.

A system and method for determining a correlation between sleep apnea and sudden cardiac death. One embodiment of the method of the invention can include predicting sudden cardiac death in a patient being monitored for sleep apnea by acquiring respiration data and electrocardiogram data from the patient and analyzing the respiration data and the electrocardiogram data to determine a correlation between sleep apnea and sudden cardiac death.

The present invention provides novel compounds of Formula I and salts, hydrates, solvates, complexes, and prodrugs thereof. The present invention further provides methods for synthesizing compounds of Formula I. The invention additionally provides pharmaceutical compositions comprising the compounds of Formula I and methods of using the pharmaceutical compositions of Formula I to treat and prevent disorders and diseases associated with the RyR receptors that regulate calcium channel functioning in cells. Such disorders and diseases include, by way of example only, cardiac disorders and diseases, skeletal muscular disorders and diseases, cognitive disorders and diseases, malignant hyperthermia, diabetes, and sudden infant death syndrome. Cardiac disorder and diseases include, but are not limited to, irregular heartbeat disorders and diseases; exercise-induced irregular heartbeat disorders and diseases; sudden cardiac death; exercise-induced sudden cardiac death; congestive heart failure; chronic obstructive pulmonary disease; and high blood pressure. Irregular heartbeat disorders and diseases include and exercise-induced irregular heartbeat disorders and diseases include, but are not limited to, atrial and ventricular arrhythmia; atrial and ventricular fibrillation; atrial and ventricular tachyarrhythmia; atrial and ventricular tachycardia; catecholaminergic polymorphic ventricular tachycardia (CPVT); and exercise-induced variants thereof. Skeletal muscular disorder and diseases include, but are not limited to, skeletal muscle fatigue, exercise-induced skeletal muscle fatigue, muscular dystrophy, bladder disorders, and incontinence. Cognitive disorders and diseases include, but are not limited to, Alzheimer's Disease, forms of memory loss, and age-dependent memory loss.

The present invention provides novel compounds of Formula I and salts, hydrates, solvates, complexes, and prodrugs thereof. The present invention further provides methods for synthesizing compounds of Formula I. The invention additionally provides pharmaceutical compositions comprising the compounds of Formula I and methods of using the pharmaceutical compositions of Formula I to treat and prevent disorders and diseases associated with the RyR receptors that regulate calcium channel functioning in cells. Such disorders and diseases include, by way of example only, cardiac disorders and diseases, skeletal muscular disorders and diseases, cognitive disorders and diseases, malignant hyperthermia, diabetes, and sudden infant death syndrome. Cardiac disorder and diseases include, but are not limited to, irregular heartbeat disorders and diseases; exercise-induced irregular heartbeat disorders and diseases; sudden cardiac death; exercise-induced sudden cardiac death; congestive heart failure; chronic obstructive pulmonary disease; and high blood pressure. Irregular heartbeat disorders and diseases include and exercise-induced irregular heartbeat disorders and diseases include, but are not limited to, atrial and ventricular arrhythmia; atrial and ventricular fibrillation; atrial and ventricular tachyarrhythmia; atrial and ventricular tachycardia; catecholaminergic polymorphic ventricular tachycardia (CPVT); and exercise-induced variants thereof. Skeletal muscular disorder and diseases include, but are not limited to, skeletal muscle fatigue, exercise-induced skeletal muscle fatigue, muscular dystrophy, bladder disorders, and incontinence. Cognitive disorders and diseases include, but are not limited to, Alzheimer's Disease, forms of memory loss, and age-dependent memory loss.

The present invention provides methods for limiting or preventing a decrease in the level of RyR2-bound FKBP12.6 in a subject. The present invention further provides methods for treating and preventing atrial and ventricular cardiac arrhythmias, heart failure, and exercise-induced sudden cardiac death in a subject. Additionally, the present invention provides use of JTV-519 in a method for limiting or preventing a decrease in the level of RyR2-bound FKBP12.6 in a subject who has, or is a candidate for, atrial fibrillation. Also provided are uses of 1,4-benzothiazepine derivatives in methods for treating and preventing atrial and ventricular cardiac arrhythmias and heart failure in a subject, and for preventing exercise-induced sudden cardiac death. The present invention also provides methods for identifying agents for use in treating and preventing atrial fibrillation and heart failure, and agents identified by these methods.

A system and method for predicting sudden cardiac death. The system includes a patient monitoring station, a Holter analysis workstation, and a hospital information network. The Holter analysis workstation being operative to apply a plurality of data analysis algorithms to create a sudden cardiac death report. The method applies a first data analysis technique and a second data analysis technique to electrocardiographic data to produce an indication of sudden cardiac death risk.

A composition is provided which contains policosanol and omega-3 fatty acids and which may be used for treating and or reducing hypercholesterolemic diseases, total cholesterol, LDL-cholesterol, LDL / HDL ratio, triglycerides, coronary heart disease (heart attacks and strokes), sudden cardiac death, ventricular fibrillation, tachycardia, hypertension, inflammation, thrombosis, deep-vein thrombosis, stroke, macular degeneration, autoimmune and / or immunoregulatory diseases, cardiovascular diseases, anxiety, depression and / or neurodegenerative disorders, and / or raise HDL cholesterol in humans and animals. The method comprises administering policosanol and omega-3 fatty acids which together effectively lower the LDL / HDL cholesterol ratio. Typically, the administered composition includes about 0.1-10:1 parts by weight of policosanol to omega-3 fatty acids.

Previously unknown mutations of the KCNH2, SCN5A and KCNQ1 genes are disclosed which are involved in ion channel disruptions associated with short QT syndrome, long QT syndrome, Brugada syndrome and progressive conduction disease. These mutations are utilized to diagnose and screen for short QT syndrome, long QT syndrome, Brugada syndrome and progressive conduction disease, thus providing modalities for diagnosing sudden cardiac death and / or predicting susceptibility to sudden cardiac death. Nucleic acid probes are provided which selectively hybridize to the mutant nucleic acids described herein. Antibodies are provided which selectively bind to the mutant proteins described herein. The mutations described herein are also utilized to screen for compounds useful in treating the symptoms manifest by such mutations.

Exercise-induced T-wave alternans (TWA) in coronary artery disease patients reflects significant levels of spatial heterogeneity of repolarization, which may underlie the predictive utility of TWA in estimating risk of sudden cardiac death. A method for assessing spatial heterogeneity of repolarization of a heart of a patient includes the following steps: simultaneously sensing an ECG signal from each of a plurality of spatially separated leads attached to the patient; for a plurality of N beats in each of the ECG signals, identifying a JT interval of each beat; and for corresponding ones of the JT intervals of the ECG signals, calculating a second central moment indicative of spatial heterogeneity of repolarization.

The present invention provides novel 1,4-benzothiazepine intermediates and derivatives, methods for synthesizing same, and methods for assaying same. The present invention also provides methods for using these novel compounds to limit or prevent a decrease in the level of RyR2-bound FKBP12.6 in a subject; to prevent exercise-induced sudden cardiac death in a subject; and to treat or prevent heart failure, atrial fibrillation, or exercise-induced cardiac arrhythmia in a subject. The present invention further provides methods for identifying an agent that enhances binding of RyR2 and FKBP12.6, and agents identified by these methods. Additionally, the present invention provides methods for identifying agents for use in treating or preventing heart failure, atrial fibrillation, or exercise-induced cardiac arrhythmia, and in preventing exercise-induced sudden cardiac death. Also provided are agents identified by such methods.

The invention discloses a method for obtaining the weight value matrix of the artificial neural network for sudden death risk prediction. The sudden cardiac death database and the MIT-BIH normal sinus rhythm database are constructed into training data samples and cross-validation samples, and each layer of the artificial neural network is randomly set first. Input training data samples to iteratively correct the weight values ​​of each layer until the training error is less than a specified value, find the weight value matrix that can predict the risk of sudden death, and then use the weight value matrix to add the weight value matrix to the original artificial neural network to construct a new model. The artificial neural network, and then use the collected target human ECG signal as data, process the human ECG signal to obtain the target human feature vector X, and perform prediction calculations according to the target human feature vector X and the new artificial neural network, and finally Get the predicted value.

The invention relates to the field of molecular biology and medical science, and in particularly relates to a sudden cardiac death mutant gene detection kit which is high in accuracy and good in predictability. The kit is used for performing polymorphism detection on 12 SNP sites of 8 major genes related to sudden cardiac death; three forward and reverse specific primers are respectively adopted for each SNP site by combining the characteristics of specific allelic gene PCR (polymerase chain reaction) and temperature gradient descent PCR; and the mutation of the 12 SNP sites can be simultaneously determined by virtue of program amplification of the temperature gradient descent PCR and agarose gel electrophoretic analysis. The detection kit provided by the invention is strong in specificity, high in detection rate, high in efficiency and low in cost, and can be used for screening high-risk population of sudden cardiac death, evaluating the risk degree of having the sudden cardiac death for a detected patient, and making clear pathogenic factors of patient sudden death from a gene level, thereby providing a new way of preventing, diagnosing and treating clinical sudden death.

A method and apparatus for using vagal stimulation to detect autonomic tone and assess a patient's risk of sudden cardiac death (SCD) are presented. The method involves stimulating the patient's vagus nerve in order to induce a drop in arterial blood pressure, which simulates the patient's cardiovascular response to a premature ventricular contraction (PVC). Sinus rhythm data just before and immediately following the stimulation is recorded and analyzed for a degree of heart rate turbulence (HRT) in order to detect abnormalities in autonomic tone and assess the risk of SCD. In an embodiment, the method is implemented in an implantable cardiac device (ICD), which can deliver arrhythmia prevention therapy based on the risk of SCD. The method can assess the patient's vagal activity on-demand by measuring HRT without relying on naturally occurring PVCs and eliminates the risk of causing arrhythmia associated with artificially inducing PVCs in order to measure HRT.

The invention relates to a non-invasive attached telemetering electrocardiographic recording method having an ultra-long record period and an ultra-high storage capacity. By using the method, characteristic values of electrocardiographic waves can be safely, stably and clearly acquired under the natural physiological state of a human body within a long period (more than 15 days), microvolt-level measurements of T-wave alternans can be acquired, and the collection, processing and high-capacity storage of electrocardiographic waves can be completed; and multiple electrocardiographic recording pasters can be used to realize the simultaneous recording of multi-channel body surface electrocardiograms, and a computer data processing and analysis system can complete the data monitoring and analysis, image display, data storage and printing and output of the recorded signals and realize the networking transmission of the electrocardiosignals. The clinical indications of the device include: symptoms related to suspected arrhythmia; determination of arrhythmia property, and completion of reasonably evaluating anti-arrhythmia treatment and monitoring myocardial ischemia; evaluation of anemic heart disease treatment measures; instructions to acute myocardial infarction patients before leaving hospital and during convalescence; and installation, detection and function assessment of sudden cardiac death and heart pacemakers.

A method and apparatus for the quantitative determination of an individual's risk for sudden cardiac death (SCD) is described. Risk stratification is accomplished (and may have a sensitivity and specificity of greater than about 90%) by determining the presence in any individual being tested for SCD risk of sequences identified herein to correlate quantitatively with SCD risk. Both the number of such sequences present and their alignment scores (similarity) with the SCD risk sequence ensemble are used to calculate quantitative SCD risk.

The present invention provides novel 1,4-benzothiazepine intermediates and derivatives, methods for synthesizing same, and methods for assaying same. The present invention also provides methods for using these novel compounds to limit or prevent a decrease in the level of RyR2-bound FKBPl2.6 in a subject; to prevent exercise-induced sudden cardiac death in a subject; and to treat or prevent heart failure, atrial fibrillation, or exercise-induced cardiac arrhythmia in a subject. The present invention further provides methods for identifying an agent that enhances binding of RyR2 and FKBP12.6, and agents identified by these methods. Additionally, the present invention provides methods for identifying agents for use in treating or preventing heart failure, atrial fibrillation, or exercise-induced cardiac arrhythmia, and in preventing exercise-induced sudden cardiac death. Also provided are agents identified by such methods.

The invention is a method for identifying proteins associated with sudden cardiac death (SCD) and for assessing a patient's risk of SCD by determining the amount of one or more SCD-associated proteins in the patient. Typically, the patient submits a sample, such as a blood sample, which is tested for one or more SCD-associated proteins. Based upon the results of the tests, the patient's risk of SCD may be assessed.

The present invention discloses a rapid gene detection kit for sudden cardiac death. The kit comprises 7 SNP polymorphism detections corresponding to genes such as KCNE1, KCNH2, SCN5A, KCNJ11, NUP155, CACNA1C and CACNB2B. The present invention further discloses a rapid gene detection method for sudden cardiac death. According to the present invention, semi-nested AS-PCR amplification and agarose gel electrophoresis detection are performed, and genotyping is performed according to the DNA electrophoresis bands to screen the individual with the potential sudden cardiac death risk so as to achieve the purpose of sudden cardiac death prevention; and the method has characteristics of simple operation, short detection time, low cost, high sensitivity, strong specificity, good social benefits and broad application prospects.